Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer.

Conclusion: The treatment of RCC is undergoing a paradigm shift from sole use of small molecule antiangiogenesis TKIs as first-line therapy to include newly approved agents for second-line and third-line therapy that now involve the mTOR pathway and immune checkpoint blockade drugs for patients with advanced RCC. PMID: 31258426 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/31258426?dopt=Abstract

Source: Ochsner Journal - July 3, 2019 Category: General Medicine Tags: Ochsner J Source Type: research